GSK plc (GSK) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, GSK plc's filing signal continuing positive.

GSK plc is a global biopharma company focused on preventing and treating disease through specialty medicines, vaccines, and general medicines. The company leverages its expertise in immunology and advanced technologies to develop innovative treatments across four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. GSK aims to positively impact the health of 2.5 billion people by the end of the decade, driven by a pipeline of 58 assets, with over half secured through business development. With 66,800 employees across 70 countries and 33 manufacturing sites, GSK reported total sales of over £32 billion in 2025, with Specialty Medicines accounting for over 40% of sales and demonstrating double-digit growth.

Revenue is primarily driven by its Specialty Medicines portfolio, which includes significant contributions from HIV treatments, respiratory and immunology therapies, and oncology drugs. Vaccine sales, particularly Shingrix and Arexvy, also contribute substantially to revenue, while General Medicines provide a stable revenue base.